407
Participants
Start Date
Not specified
Study Completion Date
October 31, 2007
tiotropium-bromide
Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
Boehringer Ingelheim Investigational Site, Barnaul
Boehringer Ingelheim Investigational Site, Chelyabinsk
Boehringer Ingelheim Investigational Site, Irkutsk
Boehringer Ingelheim Investigational Site, Kazan'
Boehringer Ingelheim Investigational Site, Kemerovo
Boehringer Ingelheim Investigational Site, Khabarovsk
Boehringer Ingelheim Investigational Site, Krasnodar
Boehringer Ingelheim Investigational Site, Krasnodar Region
Boehringer Ingelheim Investigational Site, Krasnoyarsk
Boehringer Ingelheim Investigational Site, Kursk
Boehringer Ingelheim Investigational Site, Mezjdurechensk
Boehringer Ingelheim Investigational Site, Moscow
Boehringer Ingelheim Investigational Site, Moscow Region
Boehringer Ingelheim Investigational Site, Nizhny Novgorod
Boehringer Ingelheim Investigational Site, North Ossetia
Boehringer Ingelheim Investigational Site, Novosibirsk
Boehringer Ingelheim Investigational Site, Omsk
Boehringer Ingelheim Investigational Site, Perm
Boehringer Ingelheim Investigational Site, Rostov-on-Don
Boehringer Ingelheim Investigational Site, Ryazan
Boehringer Ingelheim Investigational Site, S-Petersburg
Boehringer Ingelheim Investigational Site, Samara
Boehringer Ingelheim Investigational Site, Saratov
Boehringer Ingelheim Investigational Site, Stavropol
Boehringer Ingelheim Investigational Site, Stavropol Region, North Ossetia
Boehringer Ingelheim Investigational Site, Tomsk
Boehringer Ingelheim Investigational Site, Tyumen
Boehringer Ingelheim Investigational Site, Ufa
Boehringer Ingelheim Investigational Site, Vladivostok
Boehringer Ingelheim Investigational Site, Volgograd
Boehringer Ingelheim Investigational Site, Voroneg
Boehringer Ingelheim Investigational Site, Yaroslavl
Boehringer Ingelheim Investigational Site, Yekaterinburg
Lead Sponsor
Boehringer Ingelheim
INDUSTRY